FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2748373020> ?p ?o ?g. }

• W2748373020 endingPage "73086" @default.
• W2748373020 startingPage "73079" @default.
• W2748373020 abstract "// Weimin Xie 1, * , Tianjia Li 2, * , Jing Yang 3 , Mengmeng Shang 4 , Ying Xiao 5 , Qian Li 6 and Jiaxin Yang 1 1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 2 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 3 Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Hunan Province, Changsha, China 4 Department of Scientific Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 5 Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 6 Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China * These authors contributed equally to this work Correspondence to: Jiaxin Yang, email: yangjiaxin4022@163.com Keywords: metformin, endometrial cancer, survival outcomes, meta-analysis Received: June 10, 2017      Accepted: August 04, 2017      Published: August 22, 2017 ABSTRACT Previous studies have evaluated the effects of metformin use on survival outcomes in endometrial cancer, but their results are inconsistent. We conducted a systematic review and meta-analysis to provide a quantitative assessment of the drug’s effects based on available evidence. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify relevant studies that evaluated the association between metformin use on survival outcomes in endometrial cancer. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association of metformin use with overall survival and with progression-free survival using a fixed-effects model. A total of nine studies involving 2,016 patients with endometrial cancer were identified. In a meta-analysis of eight studies involving 1,594 individuals, metformin use was associated with significant improvements in overall survival (HR, 0.51; 95% CI, 0.41 to 0.64). Metformin users similarly showed improved progression-free survival in a meta-analysis of two studies involving 632 individuals (HR, 0.63; 95% CI, 0.46 to 0.87). In conclusion, endometrial cancer patients who use metformin show improved overall survival and progression-free survival. Further studies are required to confirm the full potential effects of metformin use on survival outcomes in endometrial cancer." @default.
• W2748373020 created "2017-08-31" @default.
• W2748373020 creator A5015536291 @default.
• W2748373020 creator A5052316896 @default.
• W2748373020 creator A5055937827 @default.
• W2748373020 creator A5060469228 @default.
• W2748373020 creator A5073922452 @default.
• W2748373020 creator A5073945974 @default.
• W2748373020 creator A5079488362 @default.
• W2748373020 date "2017-08-22" @default.
• W2748373020 modified "2023-09-26" @default.
• W2748373020 title "Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis" @default.
• W2748373020 cites W1527753191 @default.
• W2748373020 cites W1537490735 @default.
• W2748373020 cites W1665239623 @default.
• W2748373020 cites W1776492638 @default.
• W2748373020 cites W1926256737 @default.
• W2748373020 cites W1963738625 @default.
• W2748373020 cites W1967463095 @default.
• W2748373020 cites W1969542174 @default.
• W2748373020 cites W1969869199 @default.
• W2748373020 cites W1969969925 @default.
• W2748373020 cites W1970614140 @default.
• W2748373020 cites W1971931804 @default.
• W2748373020 cites W1974323653 @default.
• W2748373020 cites W1989622225 @default.
• W2748373020 cites W1989742048 @default.
• W2748373020 cites W2007872832 @default.
• W2748373020 cites W2008425254 @default.
• W2748373020 cites W2043669151 @default.
• W2748373020 cites W2044649390 @default.
• W2748373020 cites W2047444621 @default.
• W2748373020 cites W2062353094 @default.
• W2748373020 cites W2065267852 @default.
• W2748373020 cites W2075642745 @default.
• W2748373020 cites W2076879817 @default.
• W2748373020 cites W2088095316 @default.
• W2748373020 cites W2093294518 @default.
• W2748373020 cites W2119605658 @default.
• W2748373020 cites W2144399303 @default.
• W2748373020 cites W2146218042 @default.
• W2748373020 cites W2146654374 @default.
• W2748373020 cites W2170843315 @default.
• W2748373020 cites W2235523093 @default.
• W2748373020 cites W2288788281 @default.
• W2748373020 cites W2331993519 @default.
• W2748373020 cites W2339623449 @default.
• W2748373020 cites W2468315311 @default.
• W2748373020 cites W2493221114 @default.
• W2748373020 cites W2543204292 @default.
• W2748373020 cites W2589747936 @default.
• W2748373020 cites W2593712675 @default.
• W2748373020 cites W2603327649 @default.
• W2748373020 cites W2613571143 @default.
• W2748373020 doi "https://doi.org/10.18632/oncotarget.20388" @default.
• W2748373020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641193" @default.
• W2748373020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069850" @default.
• W2748373020 hasPublicationYear "2017" @default.
• W2748373020 type Work @default.
• W2748373020 sameAs 2748373020 @default.
• W2748373020 citedByCount "11" @default.
• W2748373020 countsByYear W27483730202018 @default.
• W2748373020 countsByYear W27483730202019 @default.
• W2748373020 countsByYear W27483730202020 @default.
• W2748373020 countsByYear W27483730202022 @default.
• W2748373020 countsByYear W27483730202023 @default.
• W2748373020 crossrefType "journal-article" @default.
• W2748373020 hasAuthorship W2748373020A5015536291 @default.
• W2748373020 hasAuthorship W2748373020A5052316896 @default.
• W2748373020 hasAuthorship W2748373020A5055937827 @default.
• W2748373020 hasAuthorship W2748373020A5060469228 @default.
• W2748373020 hasAuthorship W2748373020A5073922452 @default.
• W2748373020 hasAuthorship W2748373020A5073945974 @default.
• W2748373020 hasAuthorship W2748373020A5079488362 @default.
• W2748373020 hasBestOaLocation W27483730201 @default.
• W2748373020 hasConcept C10885799 @default.
• W2748373020 hasConcept C17744445 @default.
• W2748373020 hasConcept C191935318 @default.
• W2748373020 hasConcept C199539241 @default.
• W2748373020 hasConcept C2778304055 @default.
• W2748373020 hasConcept C2779234561 @default.
• W2748373020 hasConcept C512399662 @default.
• W2748373020 hasConcept C54355233 @default.
• W2748373020 hasConcept C71924100 @default.
• W2748373020 hasConcept C86803240 @default.
• W2748373020 hasConceptScore W2748373020C10885799 @default.
• W2748373020 hasConceptScore W2748373020C17744445 @default.
• W2748373020 hasConceptScore W2748373020C191935318 @default.
• W2748373020 hasConceptScore W2748373020C199539241 @default.
• W2748373020 hasConceptScore W2748373020C2778304055 @default.
• W2748373020 hasConceptScore W2748373020C2779234561 @default.
• W2748373020 hasConceptScore W2748373020C512399662 @default.
• W2748373020 hasConceptScore W2748373020C54355233 @default.
• W2748373020 hasConceptScore W2748373020C71924100 @default.
• W2748373020 hasConceptScore W2748373020C86803240 @default.
• W2748373020 hasIssue "42" @default.
• W2748373020 hasLocation W27483730201 @default.
• W2748373020 hasLocation W27483730202 @default.

• next